

**Rahul Seth, D.O.**  
Assistant Professor  
SUNY Upstate Medical University  
750 East Adams Street  
Syracuse, New York 13210  
Telephone – 315-464-8200  
Email – [sethr@upstate.edu](mailto:sethr@upstate.edu)

**PERSONAL DATA:**

Born: April 1, 1970  
Citizenship: United States  
Marital Status: Married  
Children: Two

**EMPLOYMENT:**

2009 – Present      Assistant Professor: SUNY Upstate Medical University  
Syracuse, New York  
2005 – 2009      Practicing Oncologist: Cancer and Blood Specialist of Long Island  
Greenlawn, New York

**AFFILIATIONS:**

2009 – Present      Department of Medicine MSG at SUNY HSC at Syracuse, Inc., d/b/a  
University Physicians, 140 West 6<sup>th</sup> Street, Suite 110, Oswego, NY 13126  
2009 – Present      Department of Medicine MSG at SUNY HSC at Syracuse, Inc., d/b/a  
University Physicians, 1000 East Genesee Street, Suite 403  
Syracuse, NY 13210

**EDUCATION:**

1995 – 1999      New York College of Osteopathic Medicine, Old Westbury, New York  
Doctor of Osteopathy  
1992-1995      Brown University, Providence, Rhode Island  
Master of Science, Biochemistry & Toxicology  
Thesis: Vitamine A in Murine Reproduction  
Mentor: Kim Boekelheide, M.D., Ph.D.  
1988-1991      Carnegie Mellon University, Pittsburgh, Pennsylvania  
Bachelor of Science, Biology

**POSTDOCTORAL TRAINING:**

2002-2005      Hematology & Oncology Fellowship  
Department of Oncology and Hematology  
Stony Brook University Hospital, Stony Brook, New York  
1999-2002      Internal Medicine Residency  
General Medicine Department  
Stony Brook University Hospital, Stony Brook, New York

**COMMITTEES:**

2009 – Present IRB Committee, SUNY Upstate Medical University  
2004 – 2005 Quality of Life Committee  
2004 – 2005 Bone Marrow Transplant Advisory Committee  
2002 – 2005 Pain Management Sub-Committee  
2002 – 2005 Anti-Emetic Sub-Committee

**PUBLICATIONS:**

“Granisetron vs. Dolasetron for acute chemotherapy-induced nausea and vomiting (CINV) in high and moderately high emetogenic chemotherapy: an open-label pilot study” Tan M., Xu R., Seth R., Current Medical Research and Opinion, 20(6):878-882, 2004.

“Guide to Medical Oncology at Stony Brook University Hospital” Xu R., Seth R., Tan M., et al: First Edition, Stony Brook University Press, July 2001.

“Male infertility caused by epididymal dysfunction in transgenic mice expressing a dominant negative mutation of retinoic acid receptor alpha 1” Costa SL, Boekelheide K, Vnaderhyden BC, Seth R., et al., Biology of Reproduction 56(4): 985-990, 1997.

“Malignant phyllodes tumor of the breast presenting with hypoglycemia: a case report and literature review” Pacioles T, Seth R, Orellana C, John I, Panuganty V, Dhaliwal R, Cancer Manag Res, 6:467-73, 2014.

**POSTERS:**

“Hospital wide Conversion of Epoetin alfa to Darbepoetin alfa: University Hospital Experience” Abstract/Poster Presentation at ASHIP Mid-Year Clinical Meeting, Tan M., Seth R., Weber S., Chem B. New Orleans, 2003

“Efficacy of Kytril versus Anzemet for Highly Emetogenic Chemotherapy” Abstract/Poster presentation at MASCC Annual Meeting, Tan M., Seth R., Xu R. Boston 2002

**LECTURES:**

November 2003 “Management of Cancer Pain” Stony Brook University Department of Oncology,  
June 2003 “Velcade and Clinical Application” Stony Brook University Department of Oncology  
June 2003 “Current Opinion and Updates in Colon Cancer” Stony Brook University Department of Oncology  
January 2003 “Crystal Storing Histiocytes” Stony Brook University Department of Oncology  
November 2002 Anemia Management in Cancer Patients” Oncology Nursing Association Monthly Meeting

**RESEARCH:**

- 2003 – Present            Autoimmune Disease Response to Bone Marrow Transplant, Dr. Douglas Gladstone
- 2001 – 2002             Dendritic Cells Response to Cytotoxic Drugs, Dr. Amitabha Mazumder

**FUNDED RESEARCH:**

Otsuka Protocol 287-11-201 – Phase 2 Placebo-Controlled Double-Blind Trial of Dasatinib Added to Gemcitabine for Subjects with Locally- Advanced Pancreatic Cancer

Janssen Research & Development, LLC Protocol ET743-SAR-2007 – A Randomized Controlled Study of YONDELIS® (Trabectedin) or Dacarbazine for the Treatment of Advanced Liposarcoma or Leiomyosarcoma

EMD Serono Protocol EMR200592-001 – A Randomized, Double-Blind, Phase III Study of the Efficacy and Safety of Gemcitabine in Combination with TH-302 Compared with Gemcitabine in Combination with Placebo in Previously Untreated Subjects with Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma (MAESTRO: TH-302 in the treatment of Metastatic or locally Advanced unresectable pancreatic adenocarcinoma)

Bayer Protocol 15983 – A Randomized, Double-Blind, Placebo-Controlled Phase III Study of Adjuvant Regorafenib Versus Placebo for Patients with Stage IV Colorectal Cancer After Curative Treatment of Liver Metastases

Celgene/PPD ABI-007-PANC-003- A Phase 3, Multicenter, Open-Label, Randomized Study of Nab®-Paclitaxel Plus Gemcitabine Versus Gemcitabine Alone as Adjuvant Therapy in Subjects with Surgically Resected Pancreatic Adenocarcinoma

Celgene Health-Related Quality of Life among People with Metastatic Pancreatic Cancer  
Eleison: EP-GF-301- A Randomized Phase 3 Study of the Efficacy and Safety of Glufosfamide Compared with Fluorouracil (5-FU) in Patients with Metastatic Pancreatic Adenocarcinoma Previously Treated with Gemcitabine

ACCRU - BBI608-336: A Phase III Randomized Double-Blind, Placebo-Controlled Clinical Trial of BBI608 plus Weekly Paclitaxel vs Placebo plus Weekly Paclitaxel in Adult Patients with Advanced, Previously Treated Gastric and Gastro-Esophageal Junction Adenocarcinoma

Prometheus – 10PLK 13 – PROCLAIM: Proleukin Observation Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy

Prometheus – 12PLK02 - Open-Label, Randomized, Multi-Center Study Comparing the Sequence of High Dose Aldesleukin (Interleukin-2) and Ipilimumab (Yervoy®) in Patients with Metastatic Melanoma

Merck - 045-02 – A Phase 3 Trial of Pembrolizumab (MK-3475) vs Paclitaxel or Docetaxel, Vinflunine in Recurrent/Progressive Metastatic Urothelial Cancer.

OncoMed - M18-006 - YOSEMITE: A 3-Arm Phase 2 Double-Blind Randomized Study of Gemcitabine, Abraxane<sup>®</sup> Plus Placebo versus Gemcitabine, Abraxane<sup>®</sup> plus 1 or 2 Truncated Courses of Demeizumab in Subjects with 1<sup>st</sup>-line Metastatic Pancreatic Ductal Adenocarcinoma

Celgene/PPD - ABI-007-PANC-007 - *nab*-Paclitaxel (Abraxane<sup>®</sup>) plus gemcitabine in subjects with locally advanced pancreatic cancer (LAPC): An international, open-label, multi-center, phase 2 study (LAPACT)

Immunomedics - IMMU 107-04 - An International, Multi-Center, Double-Blind, Randomized, Phase III Trial of <sup>90</sup>Y-Clivatuzumab Tetraxetan plus Low-Dose Gemcitabine Versus Placebo plus Low-Dose Gemcitabine in Patients with Metastatic (Stage IV) Pancreatic Adenocarcinoma Who Received at Least Two Prior Treatments (PANCRIT-1)

**BOARD CERTIFICATION:**

2006 – 2016 Oncology Board Certified